CS MEDICA postpones its Annual Report to February 24, 2024 and the Annual General Meeting to February 29, 2024

CS MEDICA has chosen to delay the release of its Annual Report to Wednesday, February 14, 2024.  Subsequently, the Annual General Meeting has been moved to Thursday, February 29, 2024.

CS MEDICA A/S, a MedTech company that focuses on treating pain, autoimmune diseases, and stress-related disorders with therapeutic CBD/cannabinoids, announces the rescheduling of its Annual Report to Wednesday, February 14, 2024. Consequently, the Annual General Meeting is also rescheduled and will now occur on Thursday, February 29, 2024.

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA is a Danish-based MedTech company operating within research, development, manufacturing, commercializing, and operating within the pharmaceutical industry. The company combines science and nature with the purpose of creating over-the-counter treatments to fight autoimmune and stress-related diseases, built upon our knowledge of the endocannabinoid system, patients' needs, and our experience in the pharmaceutical industry. We do so by pioneering scientific breakthroughs, expanding access to our treatments, understanding patients globally, and working to prevent the pain caused by the diseases we treat.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.

Tags: